Orion Pharma Limited announcements
187 Dhaka Stock Exchange announcements for Orion Pharma Limited (ORIONPHARM) since 2013: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2025 (17).
- Qualified Opinion, Emphasis of Matter and Other Matter
The auditor of the company has given the Qualified Opinion, Emphasis of Matter and Other Matter paragraph in the audited financial statements of the company for the year ended June 30, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/ORIONPHARM_2025.pdf
- Change of AGM and EGM Venue
Refer to their earlier news disseminated by DSE on 12.11.2025 regarding dividend declaration & EGM for Related Party Transactions and company name change, the company has further informed that due to unavoidable circumstances, the venue of the forthcoming AGM and EGM has been changed to " Extended Corporate Office: (3rd Floor) 1327 Tejgaon Industrial Area, Dhaka-1208" from " Orion House, 153-154 Tejgaon Industrial Area, Dhaka-1208". (cont.) (Cont. News of ORIONPHARM): It is to be noted that all other information relating to the AGM and EGM, including the date, time, and agenda, shall remain unchanged. (end)
- Resumption after Record Date
Trading of the shares of the company will resume on 07.12.2025.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 04.12.2025 for AGM and EGM.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle from 01.12.2025 to 03.12.2025 and trading of the shares will remain suspended on record date i.e., 04.12.2025 for AGM & EGM.
- Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. (0.30) for July-September 2025 as against Tk. 0.24 for July-September 2024; Consolidated NOCFPS was Tk. 0.65 for July-September 2025 as against Tk. 1.85 for July-September 2024. Consolidated NAV per share (including revaluation surplus) was Tk. 89.86 as on September 30, 2025 and Tk. 86.09 as on June 30, 2025. Consolidated NAV per share (excluding revaluation surplus) was Tk. 82.09 as on September 30, 2025 and Tk. 78.34 as on June 30, 2025. (cont.) (Cont. news of ORIONPHARM): Reasons for deviation: EPS: The Consolidated Earnings Per Share (EPS) decreased compared to the previous period, mainly because no revenue was generated from two subsidiary companies during this period. NOCFPS: The Consolidated Net Operating Cash Flow per Share (NOCFPS) decreased compared to the previous period, mainly due to a significant decline in consolidated sales revenue, which negatively impacted cash collection during this period. (end)
- Dividend Declaration
The Board of Directors has recommended No Dividend for the year ended June 30, 2025. Date of AGM: 23.12.2025, Time of AGM: 4:00 PM, Venue: Hybrid Platform at Orion House, 153-154 Tejgaon I/A, Dhaka-1208. Record Date of AGM: 04.12.2025. The Company has also reported Consolidated EPS of Tk. (1.77), Consolidated NAV per share (including revaluation surplus) of Tk. 86.09, Consolidated NAV per share (excluding revaluation surplus) of Tk. 78.34, (cont.) (cont. news of ORIONPHARM): and Consolidated NOCFPS of Tk. 4.72 for the year ended June 30, 2025, as against Consolidated EPS of Tk. 1.36, Consolidated NAV per share (including revaluation surplus) of Tk. 92.05, Consolidated NAV per share (excluding revaluation surplus) of Tk. 84.27, and Consolidated NOCFPS of Tk. 6.78 for the year ended June 30, 2024. (end)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (12.11.2025) following its corporate declaration.
- EGM for Related Party Transactions and company name change
The Board of Directors of the company has considered and recommended the proposals for approval of the shareholders regarding Related Party Transactions for the financial year ended 2025 and the change of the Company's name from Orion Pharma Limited to Orion Pharma PLC to comply with the requirements of the Companies (Second Amendment) Act, 2020 dated November 26, 2020. (cont.) (cont. news of ORIONPHARM): In this regard, the Board has also decided to convene an Extra-Ordinary General Meeting (EGM) to obtain the shareholders' approval for the proposed change of name. Date of EGM: 23.12.2025, Time of EGM: 4:45 PM, Venue of EGM: Hybrid Platform at Orion House, 153-154 Tejgaon I/A, Dhaka-1208. Record Date of EGM: 04.12.2025. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 15, 2025 at 4:00 PM to consider, among others, Un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2025.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 11, 2025 at 4:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2025.
- Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 0.02 for January-March 2025 as against Tk. 0.42 for January-March 2024; Consolidated EPS was Tk. (0.18) for July 2024-March 2025 as against Tk. 1.65 for July 2023-March 2024. Consolidated NOCFPS was Tk. 5.27 for July 2024-March 2025 as against Tk. 3.09 for July 2023-March 2024. (cont.) (Continuation news of ORIONPHARM): Consolidated NAV per share (excluding Revaluation Surplus) was Tk. 81.42 as on March 31, 2025 and Tk. 84.27 as on June 30, 2024. NAV per share (including Revaluation Surplus) was Tk. 89.18 as on March 31, 2025 and Tk. 92.05 as on June 30, 2024. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2025 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
- Category Change
The Company has been placed in 'Z' category from existing 'A' category with effect from today i.e., 05.02.2025 as per provision 1(e) of BSEC Directive No. BSEC/CMRRCD/2009-193/77, dated May 20, 2024 regarding non-disbursement of the approved dividend within the stipulated time frame.
- Prohibition on providing loan facilities to purchase securities
The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase securities of Orion Pharma Ltd. with effect from today i.e., 05.02.2025 as per BSEC Directive No. BSEC/CMRRCD/2009-193/32 dated December 26, 2021.
- Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. (0.44) for October-December 2024 as against Tk. 0.47 for October-December 2023; Consolidated EPS was Tk. (0.20) for July-December 2024 as against Tk. 1.23 for July-December 2023. Consolidated NOCFPS was Tk. 4.26 for July-December 2024 as against Tk. 2.68 for July-December 2023. Consolidated NAV per share including revaluation surplus was Tk. 89.82 as on December 31, 2024 and Tk. 92.05 as on June 30, 2024. (cont.) (Continuation news of ORIONPHARM): Consolidated NAV per share excluding revaluation surplus was Tk. 82.06 as on December 31, 2024 and Tk. 84.27 as on June 30, 2024. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2025 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.